4'-Fluorouridine is a broad-spectrum orally efficacious antiviral blocking respiratory syncytial virus and SARS-CoV-2 replication
Sourimant, J.; Lieber, C.; Aggarwal, M.; Cox, R.; Wolf, J.; Yoon, J.-J.; Toots, M.; Ye, C.; Sticher, Z.; Kolykhalov, A. A.; Martinez-Sobrido, L.; Bluemling, G. R.; Natchus, M. G.; Painter, G. R.; Plemper, R. K.
Show abstract
The COVID-19 pandemic has underscored the critical need for broad-spectrum therapeutics against respiratory viruses. Respiratory syncytial virus (RSV) is a major threat to pediatric patients and the elderly. We describe 4-fluorouridine (4-FlU, EIDD-2749), a ribonucleoside analog that inhibits RSV, related RNA viruses, and SARS-CoV-2 with high selectivity index in cells and well-differentiated human airway epithelia. Polymerase inhibition in in vitro RdRP assays established for RSV and SARS-CoV-2 revealed transcriptional pauses at positions i or i+3/4 post-incorporation. Once-daily oral treatment was highly efficacious at 5 mg/kg in RSV-infected mice or 20 mg/kg in ferrets infected with SARS-CoV-2 WA1/2020 or variant-of-concern (VoC) isolate CA/2020, initiated 24 or 12 hours after infection, respectively. These properties define 4-FlU as a broad-spectrum candidate for the treatment of RSV, SARS-CoV-2 and related RNA virus infections. One-Sentence Summary4-Fluorouridine is an orally available ribonucleoside analog that efficiently treats RSV and SARS-CoV-2 infections in vivo.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants 95%
- Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2 95%
- Recapitulation of HIV-1 Env-Antibody Coevolution in Macaques Leading to Neutralization Breadth 95%
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles 96%
- A single-administration therapeutic interfering particle reduces SARS-CoV-2 viral shedding and pathogenesis in hamsters 96%
- 2-Thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.